Blood

Single-Cell Pharmacodynamic Monitoring of Ribosomal Protein S6 Phosphorylation During AC220 Therapy Demonstrates in Vivo FLT3 Inhibition in Circulating Leukemic Blasts and Accurately Detects the Development of AC220 Resistance.

Blood

Alexander E Perl, Grace R Jeschke, Catherine C Smith, James K. Mangan, Selina M. Luger, Martin Carroll

Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects the Evolution of Polyclonal and Compound BCR-ABL Mutations in Patients Who Relapse On Kinase Inhibitor Therapy.

Blood

Catherine C Smith, Michael Brown, Wendy T Parker, Kimberly Lin, Kevin Travers, Susana Wang, Susan Branford, Neil Shah

Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants.

Blood

Catherine C Smith, Elisabeth Lasater, Melissa Mccreery, Kimberly Lin, Whitney Stewart, Lauren E Damon, Alexander E Perl, Grace R Jeschke, Mayumi Sugita, Martin Carroll, Scott C. Kogan, Neil Shah

Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220.

Blood

Catherine C Smith, Jason Chin, Elisabeth Lasater, Amy L. Paguirigan, Kimberly Lin, Whitney Stewart, Sara Salerno, Lauren E Damon, Mark J. Levis, Alexander E Perl, Kevin Travers, Andrew Kasarskis, Jerald P. Radich, Neil Shah

Competitive Allele Specific TaqMan® PCR (castPCR™) Technology for Sensitive Detection of AC220-Resistant FLT3 Kinase Domain Mutations in Primary AML Patient Samples.

Blood

Willard Cheng, Elisabeth Lasater, Catherine C Smith, Mouanoutoua Mokang, Yun Bao, Neil Shah

The Order of Exposure to Cytotoxic Chemotherapy and the Proteasome Inhibitor Bortezomib Dictates the Extent of Reversal of Chemotherapy Resistance in T-ALL.

Blood

May Y. Szeto, Justin Wahlstrom, Michelle L. Hermiston

Validation of FLT3-ITD As a Therapeutic Target in Human Acute Myeloid Leukemia.

Blood

Catherine C. Smith, Jason Chin, Qi Wang, Sara Salerno, Lauren E. Damon, Jeremy P. Hunt, Mark J. Levis, Alexander E Perl, Kevin Travers, Susana Wang, Andrew Kasarskis, Eric Schadt, John Kuriyan, Neil Shah

Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects Polyclonal and Compound BCR-ABL in Patients Who Relapse on Kinase Inhibitor Therapy,.

Blood

Catherine C. Smith, Michael Brown, Jason Chin, Corynn Kasap, Sara Salerno, Lauren E. Damon, Kevin Travers, Susana Wang, Andrew Kasarskis, Eric Schadt, Neil Shah

Phospho-Specific Flow Cytometry of Fixed Whole Blood Demonstrates In Vivo FLT3 Inhibition in Circulating Leukemic Blasts During AC220 Therapy and Accurately Detects the Development of Therapeutic Resistance,.

Blood

Alexander E Perl, Grace R Jeschke, Catherine C. Smith, James K. Mangan, Selina M. Luger, Martin Carroll

PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro.

Blood

Catherine C. Smith, Alexander E Perl, Elisabeth Lasater, Chao Zhang, Grace R Jeschke, Lauren E. Damon, Martin Carroll, Neil P. Shah

Search form

You are here

Pages